darovasertib
IDE196 · LXS196 Small Molecule Target: PKC, protein kinase C, GNAQ, GNA11
IDEAYA Biosciences
Most recent annual filing: 2026-02-17
- Darovasertib / IDE849 OptimUM programs2026Darovasertib / IDE849 OptimUM programs, 2026, notable
- Darovasertib NDA filing2H 2026Darovasertib NDA filing, 2H 2026, notable
- IDE034 Ph1 interimyear-end 2026 or early 2027IDE034 Ph1 interim, year-end 2026 or early 2027, notable
- IDE849 Ph3 starttargeted year-end 2026IDE849 Ph3 start, targeted year-end 2026, routine
- IDE892 corporate updateyear-end 2026 or early 2027IDE892 corporate update, year-end 2026 or early 2027, routine
- IDE849 Ph1 topline4Q 2026IDE849 Ph1 topline, 4Q 2026, thesis-defining
- IDE892/MTAP/CDKN2A/KRAS readout4Q 2026IDE892/MTAP/CDKN2A/KRAS readout, 4Q 2026, notable
- CDKN2A program IND filing1H 2027CDKN2A program IND filing, 1H 2027, notable
- OptimUM-02 darovasertib interimmid-2027OptimUM-02 darovasertib interim, mid-2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (13 active programs)
IDE849
SHR-4849- Small Cell Lung Cancer
- Neuroendocrine Carcinoma
IDE161
- Ovarian Cancer
- Breast Cancer
- Undisclosed indication
- Small Cell Lung Cancer
- Neuroendocrine Carcinoma
IDE892
Small Molecule Target: PRMT5
IDE574
- Undisclosed indication
IDE892
IDE397 Small Molecule Target: PRMT5, MAT2A, MTAP
IDE034
- Undisclosed indication
Technology platforms
INQUIRE
Proprietary chemical library with over 200,000 compounds supporting small molecule drug discovery for precision oncology; enables structure-based drug design and molecular optimization cycles
HARMONY
Proprietary content-based machine-learning engine for molecular design and structure-activity-relationship cycles supporting precision oncology drug discovery
DECIPHER · University of California, San Diego
Dual CRISPR synthetic lethality library focused on DDR targets across tumor suppressor genes and oncogenes; evaluates ~50,000 independent gene knockout combinations for synthetic lethality target and biomarker discovery in solid tumors
PAGEO · Broad Institute
Paralogous Gene Evaluation in Ovarian Cancer platform; uses large-scale CRISPR paralog screening to evaluate functionally redundant paralogous genes across ovarian cancer subtypes for synthetic lethality target and biomarker discovery
Discontinued (8)
- IDE705 — undisclosed · GSK terminated the collaboration agreement in December 2025; company does not intend to continue clinical development of IDE705 in combination with niraparib or other PARP inhibitors
- IDE397 — Urothelial Cancer · strategic deprioritization; concluded enrollment in combination trial with Trodelvy
- IDE397 — Non-Small Cell Lung Cancer · deprioritized clinical activity with Gilead evaluating the combination of IDE397 and Trodelvy
- IDE275 — Microsatellite Instability-High Tumors · termination of collaboration with GlaxoSmithKline; strategic deprioritization
- IDE705 — undisclosed · termination of collaboration with GlaxoSmithKline; strategic deprioritization
- IDE275 — undisclosed · termination of collaboration with GlaxoSmithKline; strategic deprioritization
- IDE275 — undisclosed · termination of collaboration with GlaxoSmithKline; strategic deprioritization
- IDE892 — Non-Small Cell Lung Cancer · deprioritized clinical activity with Gilead evaluating the combination of IDE397 and Trodelvy
Biotech Distilled coverage (1)
- 2026-09-14 IDEAYA Biosciences (IDYA) - Scientific Deep Dive for Darovasertib, IDE849 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.